Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lovesac Reaffirms Fiscal 2025 Outlook: Sees Net Sales Of $700M-$770M Vs. $714.53M Estimate; Projects Diluted EPS Of $1.06-$1.59 Vs. $1.23 Estimate

Author: Benzinga Newsdesk | June 13, 2024 07:08am

The Company expects the following for the full year of fiscal 2025:

  • Net sales in the range of $700 million to $770 million.
  • Adjusted EBITDA1 in the range of $46 million to $60 million.
  • Net income in the range of $18 million to $27 million.
  • Diluted income per common share in the range of $1.06 to $1.59 on approximately 17.0 million estimated diluted weighted average shares outstanding.
  • Fiscal 2025 will contain 52 weeks versus Fiscal 2024 which contained an additional "53rd week" in the fourth quarter.

Posted In: LOVE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist